Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions
This article was originally published in PharmAsia News
As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma
You may also be interested in...
Draft intellectual property chapter of the Trans-Pacific Partnership includes a provision prohibiting signatories from denying patents solely because a product did not show enhanced efficacy over a known product.
The Singapore round of talks to build a Trans-Pacific Partnership trade deal among 11 nations concludes in Singapore with the issue of data exclusivity for innovator biologics still in limbo.
U.S. Law On 12-Year Biologics Data Exclusivity Remains Stumbling Block To Trans-Pacific Partnership Agreement
Trans-Pacific Partnership proving to be a test case for Affordable Healthcare Act’s 12-year data exclusivity provision for biologics.